Genetic and biochemical studies were carried out in 96 relatives of six independently ascertained probands with familial dysbetalipoproteinemia (FD) carrying the APOE *2 (Lysl46-+Gln) allele. Compared to noncarriers, the 40 heterozygous APOE*2(Lysl46-+G1n) allele carriers exhibited markedly increased mean levels of cholesterol and triglyceride in the very low density lipoproteins (VLDL) (1.89+0.37 vs 0.30±0.27 and 1.86±0.37 vs 0.68±0.27 mmol/liter, respectively) and plasma apolipoprotein (apo)E levels (28.1+1.6 vs 4.6±1.1 mg/dl), which is characteristic for FD.
Introduction
Apolipoprotein E (apoE) is one of the major protein constituents of chylomicron and very low density lipoprotein (VLDL) remnants, and serves as a ligand for the receptor-mediated uptake of these lipoprotein particles by hepatic lipoprotein recep-VLDL) are enriched in cholesterol, leading to a strong predisposition for coronary and/or peripheral artery disease in these patients. Clinical abnormalities like palmar xanthomas and tubero-eruptive xanthomas are present in approximately 50% of the patients at the time of initial diagnosis (4) .
Three common genetic variants of apoE were originally identified by isoelectric focusing and designated apoE2, apoE3, and apoE4 (5, 6) . Molecular characterization showed that the apoE2 and apoE4 isoforms were encoded by APOE *2 (Argl58-+Cys) and APOE*4(Cysl 2--Arg) alleles, each differing from the wild type APOE*3 allele by single point mutations at codons 158 and 112, respectively (7) (8) (9) (10) . Homozygosity for the APOE*2(Argl58-+Cys) allele is present in the vast majority of patients with FD. However, in caucasian populations only 1 to 4% of all APOE*2(Argl58-+Cys) homozygotes develop hyperlipoproteinemia. This suggests that additional genetic and/or environmental factors are required for its manifestation (11, 12) .
A number of studies demonstrated that the domain of apoE between amino acids 131-150 is responsible for the high affinity binding to the LDL receptor (13) (14) (15) (16) . This receptor binding is suggested to occur by the direct ionic binding of some of the positively charged amino acid residues in the binding domain of apoE with negatively charged amino acid residues in the ligand binding domain of the LDL receptor. Heterozygosity for apoE variants with mutations removing a positively charged amino acid in the binding domain have been described in patients with FD: apoE3(Cysl 12-+Arg;Argl42--Cys) (17, 18) , apoEl-Harrisburg(Lysl46--KGlu) (19, 20) , apoE4-Philadelphia(Glul3-'Lys;Argl45-4Cys) (21, 22) , apoE2-Christchurch(Argl36-'Ser) (23, 24) , and apoE2(Argl45-'Cys) (24, 25) . For some of these apoE variants, i.e., apoE3(Cysil2-+ Arg; Argl42-+Cys), apoEl -Harrisburg (Lys146-+Glu), and apoE4-Philadelphia( Glu 1 3-Lys; Argl45-*Cys), association with a dominant inheritance pattern of FD has been reported (18) (19) (20) 22) .
In patients of Dutch descent two additional apoE variants have been found with dominant association of FD: apoE2 (Lysl46-KGln) (26, 27) and apoE3-Leiden (28) (29) (30) (31) (32) . The apoE2(Lys146--Gln) variant was first described by Rail et al. (33) .
In a previous paper, we described the dominant inheritance of FD in APOE*3-Leiden carriers of a large multigeneration family (32) . Because a large number of gene carriers could be studied, we were able to perform statistical analyses of the expression of FD in the APOE*3-Leiden allele carriers (32) . In this study, the identification of eight probands and their family members allowed us to carry out a similar study with APOE *2 (Lysl46-{Gln) allele carriers. We performed an extensive family study on six pedigrees of FD probands with the APOE*2 (Lysl46-*Gln) allele, who probably share common ancestry. Lipid and lipoprotein analyses revealed a strong association of the APOE*2(Lysl46-{Gln) allele with FD, most likely caused by an impaired conversion of VLDL into IDL. Comparison of the present results with those obtained in our previous apoE3-Leiden family study (32) , implies that both of these two rare mutations in the APOE gene cause dominantly inherited forms of FD but along different underlying metabolic defects.
Methods
Subjects. Through the screening of hyperlipidemic patients for biochemical and genetic parameters a total number of eight, independently ascertained, FD probands were identified exhibiting heterozygosity for the rare APOE*2(Lysl46-+Gln) allele. Probands M.N., F.D., and F.V. have previously been described by Smit et al. (26, 27) , and EDTA blood samples were collected after overnight fasting. Plasma was separated from cells by centrifugation at 500 g for 10 min at room temperature, and was used for lipid and lipoprotein analysis. Secondary causes of hyperlipidemia were excluded by standard laboratory tests. Genomic DNA was isolated from leukocytes using standard procedures (34) .
APOE genotyping. APOE genotyping of the common polymorphisms at codons 112 and 158 was performed by polymerase chain reaction (PCR) of the region encompassing both polymorphic sites, digestion of the PCR products with restriction enzyme HhaI and electrophoresis on polyacrylamide gel as described earlier (30, 32, 35) .
Detection of the APOE *2 (LysJ46-+Gln) mutation. Identification of APOE*2(Lysl46-+Gln) allele carriers was performed by PCR using a mutagenic amplification primer assay (Fig. 1) . Primer 3012 5' GGC-ATCGCGGAGGAGAGCAGCT-3' (nucleotides 3848-3867, non-coding strand) was designed with a nucleotide mismatch (underlined) as compared to the wild type APOE sequence (36) . In the case of the APOE*2(Lysl46-+Gln) allele a PvuII restriction site is introduced due to a base pair substitution specific for this allele and the nucleotide mismatch in the primer. PCR (37) (38) (39) . For analysis of the polymorphic HpaI-site, located in the promoter region of the APOC1 gene (40) , PCR was performed according to Nillesen et al. (41) . Subsequently, PCR products were digested using restriction enzyme Hincd, which reveals the same polymorphism. In addition, the (TG)n(AG)m microsatellite marker in the first intron of APOC2 was analyzed by PCR, using primer set Mfd5CA/ MfdGT (42, 43 LDL-cholesterol (1.019 < d < 1.063 g/ml) was calculated using the formula: LDL-cholesterol = plasma-cholesterol -(VLDL-cholesterol + IDL-cholesterol + HDL-cholesterol).
Agarose electrophoresis for the detection of 63-VLDL was performed as described by Demacker et al. (45) .
ApoE quantification. ApoE concentrations were measured by sandwich ELISA. Affinity purified polyclonal goat anti-human apoE antibodies were used for coating. Affinity purified polyclonal rabbit anti-human apoE antibodies were used as second antibodies. As second antibody swine anti-rabbit IgG antibodies conjugated to horseradish peroxidase were used. Color development was performed using tetramethylbenzidine. Pool plasma with known apoE level and obtained from healthy individuals was used as a standard.
Statistics. For the statistical analyses we considered allele carriers and noncarriers of six different families, implying that, in a strict sense, there were only six independent observations. Therefore, to test for the statistical significance of the effect of the mutant APOE *2 (Lysl46-Gln) allele on the lipoprotein traits in these six families, we used a pedigree-based maximum likelihood method developed by Lange et al. (46) , in which for a given pedigree of n individuals a vector of observations (x) is defined and a vector of expected values [E(x)], that can depend on measured variables such as sex or measured genotype. The covariances between the residual part of the observations, i.e., the part that is not accounted for by the measured genotype, depend on the relationships between the pedigree members and on the genetic model assumed for the observations. Throughout we have modeled the variances not accounted for by the measured genotype as consisting of additive genetic and random environmental variance, recognizing that the genetic part may also reflect environmental influences shared by family members. However, our main interest is to test for the influence of the measured genotype, and not to explain the remaining variance. For a given E(x) and expected covariance matrix 1, the log likelihood of obtaining the observation vector x is:
where ' denotes matrix transpose.
The joint log-likelihood of obtaining all pedigrees is the sum of the log-likelihood of the separate pedigrees. Estimation involves selection of parameter values under a specific model that maximizes the joint likelihood of all pedigrees. The likelihoods obtained for different models can be compared with chi-squared difference tests where x2 = 2(L, -LO) and LI and Lo denote the log likelihood for the general (HI) and the constrained (HO) hypothesis. The degrees of freedom (df) for this test are equal to the number of independent parameters between HI and Ho. (47) . The Fisher package (46) was used for genetic modeling. Ascertainment correction was carried out by conditioning on the probands.
To test for the difference between the APOE*2(Lysl46-Gln) and APOE *3-Leiden allele with respect to their effect on plasma lipoprotein levels, a nested multivariate analysis of variance (MANOVA) was performed, with individuals nested within families. Data from the probands of each pedigree were discarded. Also, one pedigree with only one carrier for the APOE*2(Lys146-<Gln) mutation in addition to the proband was omitted from the analysis. To test which individual lipid traits are responsible for the difference between both groups, a univariate analysis of variance (ANOVA) was used.
Results ** Presence of xanthomas and/or coronary artery disease/peripheral after cysteamine treatment of plasma (results not shown). Similar incomplete modification patterns have been found earlier for probands M.N., F.D., and F.V. (26) . Definite identification of the APOE*2(Lysl46-*Gln) mutation in these probands was confirmed by PCR followed by PvuII digestion (Fig. 1 Extended haplotypes were constructed of the APOE-C1-C2 gene cluster for all pedigrees, using restriction enzymes HpaI, DraI, BglI, NcoI, BamHI, Avail, BanI, and TaqI. We found that in all six pedigrees shown in Fig. 2 , the APOE*2(Lysl46--Gln) mutation cosegregated with one unique haplotype that occurred only twice among eighteen unrelated non-carrier haplotypes. This unique haplotype is designated HpaIl, DraI2, BglI2, NcoIl, BamHI2, Availl, BanI2 and TaqI2, whereby 1 and 2 stand for absence and presence of cutting site, respectively. Additional evidence for the presence of a unique APOE*2 (Lysl46-KGln) allele in all pedigrees was obtained by including the (TG)n(AG)m microsatellite marker in intron 1 of APOC2 (43) . In all 40 APOE*2(Lysl46-+Gln) allele carriers, a frag- Roman numbers represent successive generations. The numbering corresponds with that in the appendix. Female and male carriers of the APOE*2(Lys146-Gln) are indicated by half filled circles and boxes, respectively. Open and closed symbols represent noncarriers and carriers, respectively. Individuals marked by a dot could not be studied. ment of 149 bp (designated allele G7) was observed, whereas this allele was not detected in any of the 56 noncarriers. In a caucasian population this allele was found to have a very low frequency of about 3% (43) .
Lipid and lipoprotein levels in carriers versus non-carriers. Plasma samples of six probands and the 96 additional family members were studied for lipid and lipoprotein parameters (see Appendix for individual data). To avoid possible ascertainment bias, in all statistical calculations the data of the probands were excluded. The descriptive statistics of allele carrying (n = 40) and noncarrying (n = 56) family members are presented in Table II Means and asymptotic standard errors were estimated from "best-fit" models using the maximum likelihood estimate procedures implemented in the Fisher program. Probands were excluded for these quantitative analyses. * All levels are expressed as mmol/liter, except BMI (kg/ mi2) and apoE (mg/100 ml).
strongly elevated. The statistical analyses of these results are presented in Table III . We considered allele carriers and noncarriers of six different families, implying that, in a strict sense, there were only six independent observations. Therefore, to test for the effect of the mutant APOE*2(Lysl46--+Gln) allele in these six families, we used a pedigree-based maximum likelihood method developed by Lange et al. (46) . The principles of this method of statistical analyses are briefly described in Methods. The statistical analyses of the lipoprotein levels (Table II) are shown in  Table III (26, 27) . Although in these studies evidence was obtained for a dominant mode of inheritance of FD, the number of APOE *2 (Lysl46-*Gln) allele carriers was too low to study the expression of FD in these carriers by statistical analyses, like we have been able to carry out for the extended multigeneration apoE3-Leiden family (32) . However, recent screening of FD patients for the presence of the APOE*2(Lysl46--+Gln) allele resulted in the identification of five additional index patients (Table I) .
From six pedigrees together, we were able to identify 40 ited. The use of nonparametric tests does not overcome this problem of nonindependent samples. However, since then we learned that with a new generation of statistical programs, e.g., Mendel and Fisher, it is possible, indeed, to study the influence of measured alleles on quantitative traits among relatives under different models. In this study we were not hampered by the limited number of independent observations (families) anymore, as we used the pedigree-based maximum likelihood method developed by Lange et al. (46) for analyzing the effect of the apoE2(Lysl46-.Gln) on quantitative lipoprotein traits relevant for FD. In addition, by using the nested multi-and univariate analysis of variance, we were also able to compare the effect of the APOE*2(Lysl46-.Gln) allele on the expression of FD with that of the previously described APOE*3-Leiden allele (32) , in an appropriate way.
The results clearly show that the apoE2(Lysl46-eGln) variant is, like the rare apoE variants mentioned above, invariably associated with the expression of FD, but the phenotypic expression varies to a large extent. Although gender does contribute to the total variance in quantitative FD-related lipoprotein traits to a certain extent, it is obvious that the APOE*2(Lysl46-eGln) allele carrier status is more important in the expression of FD characteristics in these families.
Using nested multivariate analysis of variance, we found that APOE*2(Lysl46-eGln) and APOE*3-Leiden allele carriers significantly differ with respect to the expression of FD (Table IV) : (a) in the APOE*2(Lysl46-{Gln) allele carriers, the increased lipid levels occurred mainly in the VLDL fraction rather than in the IDL fraction, whereas in the apoE3-Leiden subjects the increased plasma cholesterol is due more specifically to an elevated IDL level, like that observed in "classical" FD patients with homozygosity for the APOE*2(Arg158-Cys)
allele (48) . In addition, in the APOE*2(Lysl46-lGln) allele carriers the VLDL + IDL lipoprotein fraction is relatively enriched in triglycerides as illustrated by the much lower ratio of cholesterol to triglycerides in this fraction (Table IV) (32) and is due to an enhanced-binding affinity of the apoE3-Leiden protein to the VLDL lipoprotein fraction (49) . Such a selective accumulation of the mutant apoE protein on the VLDL and IDL lipoprotein particles has also been reported for the apoE3(Cysll2-'Arg;Argl42--'Cys) variant (50) . In contrast, in the APOE*2(Lysl46-sGln) allele carriers, a predominance of the mutant apoE protein relative to its normal apoE counterpart was not observed (26, 27) .
APPENDIX
Data of all family members including probands These differences strongly suggest different metabolic defects underlying the dominant mode of inheritance of FD for the rare apoE2(Lysl46-+Gln) and apoE3-Leiden variants. In the case of apoE3-Leiden subjects, the predominance of apoE3-Leiden converts the d < 1.019 g/ml lipoprotein fraction into "apparent" homozygosity for the binding-defective apoE3-Leiden protein. This apparent homozygosity will, possibly in combination with a modulating effect of the abundant apoE3-Leiden protein on the conformation of the remaining normal apoE, lead to an impaired receptor-mediated clearance of these lipoprotein particles from the circulation. Such a mechanism is also supported by the observation that in the apoE3-Leiden family, the APOE*2(Argl58--Cys) allele as counter allele results in a more severe FD phenotype, whereas the APOE*4(Cys 12-.Arg) allele acts in the opposite way (32) .
For the apoE2(Lysl46-+Gln) variant, this mechanism does not hold true. It has been suggested by Mahley and co-workers (51) that the loss of any positively charged amino acid residue within the receptor-binding domain of apoE, between amino acid residue 131 and 150, affects the binding of apoE to the receptor by reducing the ionic interaction. This interaction is probably not easily modified by environmental factors and lipid composition of the lipoprotein particle. As a consequence, these authors hypothesize that mutations in the 131-150 segment of apoE result in "permanent" receptor-binding defects. This hypothesis is supported by experiments using apoE variants made by site-directed mutagenesis (13 
